Post List

Health posts

(Modify Search »)

  • May 22, 2017
  • 03:00 PM

Unraveling the Mysteries of Mischievous Microbiome

by Aurametrix team in Aurametrix Blog

Science explains why some people smell worse than others despite keeping themselves squeaky clean. The body is crawling with bacteria increasing the risk for diseases for which we have unreserved levels of sympathy. It can also lead to ​unlikable conditions such as unpredictable and embarrassing outbursts of body odor - so bad it ruins social lives and careers.  But there is no cure for metabolic body odor ... Read more »

  • May 22, 2017
  • 05:13 AM

"a gluten-related subgroup of schizophrenia"?

by Paul Whiteley in Questioning Answers

A quote to begin this post: "this preliminary study demonstrates that altered AGDA [antibodies against gliadin-derived antigen] levels in the circulation are associated with schizophrenia and could serve as biomarkers for the identification of a schizophrenia subgroup that may need an alternative therapy or precision treatment."So said the findings reported by McLean and colleagues [1] (open-access) looking at an area of some interest to this blog (see here) on how dietary gluten might show something of an important relationship to at least some cases of schizophrenia. Just in case you weren't aware, there is quite a history when it comes to gluten and schizophrenia (see here) as per the very forward-thinking of people such as Curt Dohan and Karl Reichelt.Researchers on this latest occasion set about looking in a little more detail at the suggestion that circulating anti-gliadin antibodies (AGAs) reflective of an immune response to a component of dietary gluten might show some connection to schizophrenia. Indeed they note that "all the tests for circulating AGAs in schizophrenia have been developed with mixtures of full-length native gliadins consisting of ~300 amino acid residues" suggesting that such a scatter gun approach may have included epitopes "that are unlikely to survive digestion in the gut." So, they instead "measured plasma levels of IgG and IgA against indigestible peptide fragments derived from γ- and α-gliadins" in archived plasma samples from "169 patients with schizophrenia and 236 control subjects."The results - based on the use of an "In-house ELISA for antibodies against gliadin-derived antigens" - were rather intriguing. So: "There was no significant difference in the levels of plasma antibodies against native gliadins between the patient group and the control group." If I'm reading this right, this finding is in contrast to other independent research occasions [2]. Indeed, when it came to looking at both IgA and IgG plasma anti-gliadin antibodies, there was no significant difference between the schizophrenia and non-schizophrenia participants as groups.But... when it came to a specific gliadin (γ-Gliadin) derived fragment  - AAQ6C - with the amino acid sequence HPKCSIMRAPFASIVAGIGGQYRD - researchers reported on something potentially important to see: "patients with schizophrenia had significantly higher levels of plasma anti-AAQ6C IgG than control subjects." Importantly too, authors also noted that anti-psychotic medication did not appear to influence their antibody results. This was important given that seemingly all of the participants diagnosed with schizophrenia were taking one or more of this class of medicine. In line with the opening quote to this post, the authors make a preliminary foray into the possible 'biomarker' usefulness of the various anti-gluten antibodies for schizophrenia. I have to say on this point however, that the data is not that impressive as things currently stand.There is more to do when it comes to the possible effects of dietary elements containing gluten (and casein) in relation to cases of schizophrenia. This work adds something to the idea that diet can affect psychiatry/behaviour/development but what is perhaps missing is the recognition that schizophrenia is probably a heterogeneous and plural condition (see here and see here for examples) and as such, not every case is going to be gluten and/or casein-related. I do agree with the authors that more research is needed in this area alongside the idea that intervention via either dietary changes [3] and/or other options might also be on the research agenda...----------[1] McLean RT. et al. Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia. Translational Psychiatr. 2017. May 9.[2] Dickerson F. et al. Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia. Biol Psychiatry. 2010 Jul 1;68(1):100-4.[3] Jackson J. et al. A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophrenia Res. 2012;140(0):262-263.----------McLean RT, Wilson P, St Clair D, Mustard CJ, & Wei J (2017). Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia. Translational psychiatry, 7 (5) PMID: 28485731... Read more »

  • May 20, 2017
  • 06:12 AM

Gastrin-releasing peptide and autism continued

by Paul Whiteley in Questioning Answers

Yet another 'continued' or 'part 2' short post for you today, building on some previous - very preliminary research - talking about the use of gastrin-releasing peptide (GRP) and autism (see here).The authors included on the paper by Josemar Marchezan and colleagues [1] are familiar ones to this part of the autism research landscape as per the other occasions that members of this group have looked at / talked about GRP and autism in the peer-reviewed domain.GRP is all about a compound that 'does what it says on the tin' insofar as stimulating the release of gastrin from specialist cells in the stomach. This in turn leads to the secretion of gastric acid among other things and onward aids the digestion of food.This time around Marchezan et al describe the results of a controlled trial on the use of GRP (vs. placebo) in a small group of boys (N=10) diagnosed with autism. This is a step-up from their previous research efforts in this area talking about a case series report and an open (non-blinded, non-placeboed?) study. Participants were given the same amount of GRP (160 pmol/kg) over the same number of days (4 consecutive days) as that detailed in their previous studies. This time around, the Aberrant Behavior Checklist (ABC) scale was the outcome measure of choice.Results: well, let's put it one way, they weren't exactly astounding in terms of any positive effects from the use of GRP over such a short space of time. This was exemplified by the authors use of "no statistical difference" when it came to looking at quite a lot of the data obtained during the investigation comparing GRP to placebo. On the plus side there were "no adverse effects, changes in vital signs, or laboratory abnormalities associated with the use of GRP" so the whole 'first do no harm' bit seems to be intact, at least in the short-term.Whilst it would be easy to sweep such results under the 'did not work' carpet, I am however minded to go with the authors' suggestion that "further research with other designs and a larger sample size to evaluate the efficacy and safety of GRP in children with autism" would be a step forward. I say this on the basis that hypochlorhydria - low levels of gastric acid - is not something completely unknown to parts of the autism spectrum (see here) and does suggest some *possible* involvement for something like GRP in specific cases of autism.----------[1] Marchezan J. et al. A Placebo-Controlled Crossover Trial of Gastrin-Releasing Peptide in Childhood Autism. Clin Neuropharmacol. 2017 Apr 27.----------Marchezan, J., Becker, M., Schwartsmann, G., Ohlweiler, L., Roesler, R., Renck, L., Gonçalves, M., Ranzan, J., & Riesgo, R. (2017). A Placebo-Controlled Crossover Trial of Gastrin-Releasing Peptide in Childhood Autism Clinical Neuropharmacology DOI: 10.1097/WNF.0000000000000213... Read more »

Marchezan, J., Becker, M., Schwartsmann, G., Ohlweiler, L., Roesler, R., Renck, L., Gonçalves, M., Ranzan, J., & Riesgo, R. (2017) A Placebo-Controlled Crossover Trial of Gastrin-Releasing Peptide in Childhood Autism. Clinical Neuropharmacology, 1. DOI: 10.1097/WNF.0000000000000213  

  • May 19, 2017
  • 07:00 AM

Friday Fellow: Common Stinkhorn

by Piter Boll in Earthling Nature

by Piter Kehoma Boll Today things are getting sort of pornographic again. Some time ago I introduced a plant whose flowers resemble a woman’s vulva, the asian pigeonwing, and now is time to look at something of the other sex. … Continue reading →... Read more »

  • May 19, 2017
  • 04:26 AM

Injury risk and ADHD: part 2

by Paul Whiteley in Questioning Answers

Consider this short post a sort of follow-on to a previous entry on this blog concerning the elevated risk of injury following a diagnosis of attention-deficit hyperactivity disorder (ADHD). The paper in question today is that by Wu-Chien Chien and colleagues [1] who yet again [2], brought the quite significant scientific weight of the "National Health Insurance Research Database in Taiwan" to bear on this topic.In this latest paper, Chien et al relied on data from a 'subset' of the main insurance research database and found some not unexpected things: "The patients with ADHD had a 143% increased risk of overall injuries than the controls after considering all the confounding factors" and "the use of methylphenidate was associated with a 22.6% decrease in the risk of injuries in the patients with ADHD."What's more to say? Well, yet again risk of adverse issues *correlating* with a diagnosis of ADHD comes to the forefront (see here for another example). Yet again the idea that 'tackling' ADHD is a worthy goal (for many reasons) if not only to mitigate such elevated risks being presented, bearing in mind that medication "approved solely for ADHD treatment" is not some sort of magic bullet [3]. There are also other potentially important intervention options to look at (see here for example). I'm minded at this point to also bring in the recent findings reported by Borschuk and colleagues [4] talking about how comorbid asthma accompanying ADHD (yes, there is a surprisingly strong relationship between the two diagnoses) might play a role in the expression of ADHD and onwards provide some 'interesting' directions when it comes to tackling ADHD and it's elevated risk for various adverse outcomes...To close, appreciating a talent...----------[1] Chien WC. et al. The risk of injury in adults with attention-deficit hyperactivity disorder: A nationwide, matched-cohort, population-based study in Taiwan. Res Dev Disabil. 2017 Apr 27;65:57-73.[2] Kang JH. et al. Attention-deficit/hyperactivity disorder increased the risk of injury: a population-based follow-up study. Acta Paediatr. 2013 Jun;102(6):640-3.[3] Fleming M. et al. Educational and Health Outcomes of Children Treated for Attention-Deficit/Hyperactivity Disorder. JAMA Pediatr. 2017. May 1.[4] Borschuk AP. et al. The influence of comorbid asthma on the severity of symptoms in children with attention-deficit hyperactivity disorder. J Asthma. 2017 May 1:1-7.----------Chien WC, Chung CH, Lin FH, Yeh CB, Huang SY, Lu RB, Chang HA, Kao YC, Chiang WS, Chou YC, Tsao CH, Wu YF, & Tzeng NS (2017). The risk of injury in adults with attention-deficit hyperactivity disorder: A nationwide, matched-cohort, population-based study in Taiwan. Research in developmental disabilities, 65, 57-73 PMID: 28458048... Read more »

  • May 18, 2017
  • 04:40 AM

On vaccinated and un-vaccinated homeschooled children: the disappearing-reappearing-disappearing-reappearing studies

by Paul Whiteley in Questioning Answers

I originally began writing this post in the last week of November 2016 following first sight of the study abstract by Anthony Mawson and colleagues [1] and their journey into a topic that has had its fair share of discussion/argument* (*delete as appropriate) with autism in mind down the years: are vaccines or immunisation patterns potentially linked to [some] autism?As it happened, this post was shelved for some time because (a) only an abstract appeared despite a publication date accompanying the initial open-access submission in a Frontiers journal and (b) the subsequent sudden disappearance of the abstract from the publishers website following some discussions on social media about the paper and the review process (see here and see here for more information).The study then appeared in a different journal (April 2017) before once again disappearing.Now it's back - for now - in the same journal, so once again it's fodder for this blog...As I always do when it comes to any chatter specifically on this topic, I should reiterate a few things: (a) the prime directive of this blog - no clinical or medical advice is given or intended - and (b) that vaccines save lives. I know some people attribute other factors to that 'life-saving' angle when it comes to vaccines over the longer term (better health, better environment, etc), but one really only needs to look at the protective effect of the various meningitis vaccines for example, to see their results in something like real-time. I repeat again: vaccines save lives.What however does seem to be missing from at least some of the general discussion about vaccines as a whole and their very positive health effects is the fact that they are medicines. As such they are not somehow impervious to potentially producing side-effects for some people, albeit a small proportion of people who use them. The problem at the moment is, that we don't really know everything there is to know about which people might be at greater risk of side-effects than others (although some clues are emerging) and importantly, how all those side-effects may manifest. Science - metabolomic science - is however starting to tackle some aspects of these issues [2] minus too much hype at the present time.As per the title of this post, Mawson et al set about examining whether there were differences between those children who were vaccinated and those un-vaccinated across "a broad range of health outcomes." In line with the previous history hypothesising about autism and specific vaccination, the authors focused on any 'association' between vaccination status and neurodevelopmental disorders (NDD) taking into account other potentially confounding variables.The source data for those vaccinated / un-vaccinated children participants (N=666) was an anonymous online questionnaire completed by mothers of children who were members of various homeschooling organisations in four regions of the United States. Homeschooling refers to a situation where a child is educated at home outside of the mainstream education system choices. Homeschoolers were selected for study because, according to the authors, a "higher proportion are unvaccinated compared to public school children."Results: around 40% of the participants were indeed described as un-vaccinated in the Mawson cohort. This is quite a bit higher than other estimates [3] specifically looking at homeschooled children. Then to some of the details: "Vaccinated children were significantly less likely than the unvaccinated to have been diagnosed with chickenpox and pertussis." If you needed more evidence that vaccines work, that last sentence kinda provides you with it, particularly in light of what diseases like pertussis can potentially do to the most vulnerable.And then some potential controversies: vaccinated children were significantly more likely to have been diagnosed with pneumonia, otitis media, allergies and NDDs (defined as autism spectrum disorder, attention deficit hyperactivity disorder, and/or a learning disability). After some statistical adjustment for potentially confounding variables, authors reported that "vaccination, nonwhite race, and male gender were significantly associated with NDD after controlling for other factors." I might also draw your attention to the reported finding that: "preterm birth and vaccination combined was strongly associated with NDD in the final adjusted model with interaction, more than doubling the odds of NDD compared to vaccination alone." This might suggest that there are synergistic variables at work influencing any identified risk continuing a research theme [4]. Indeed, the same authors have devoted a whole other article to this finding [5] (this paper also went through the same disappearing-reappearing act too).Wearing the objective blinkers of science, this is by no means perfect research. Not only are there potential issues related to the use of an on-line questionnaire (and anonymous at that), the focus on subjective reports over inspection of more objective medical records (even though parents were asked to obtain and use their child's vaccination record(s) when completing the questionnaire), and problems associated with recall (including possible telescoping effects), there are a whole host of other issues that one could cite in relation to such research and potential biases that could/might have influenced the results (including factors such as this one). I might also add that the Mawson study did not appear to 'name names' when it came to which individual vaccines may or may not have been involved in their findings despite asking questions about if and when specific immunisations were administered to participants. Indeed authors noted: "We did not set out to test a specific hypothesis about the association between vaccination and health." Then there is also the 'reaction' angle to papers such as this one to mention; bearing in mind that science these days does not exist in some sort of social/cultural vacuum as per other very recent and very relevant examples. Cumulatively, you can see that there ... Read more »

Anthony R Mawson, Brian D Ray, Azad R Bhuiyan, & Binu Jacob. (2017) Pilot comparative study on the health of vaccinated and unvaccinated 6- to 12-year-old U.S. children. Journal of Translational Science. info:/10.15761/JTS.1000186

  • May 17, 2017
  • 11:24 AM

Dad's Impact in Infant Development

by William Yates, M.D. in Brain Posts

Mother's interaction with their infants play a key role in infant development.The independent role of fathers in infant development is less well known and studied.A recent study from the United Kingdom supports a important role for father-child interactions in infant development.Here are the main elements of the design of this study:Subjects: Families of infants with typical deliveries were recruited from maternity wards in two hospitals in the United Kingdom.Design: Home assessments were completed at 3 months and 24 months following birth making this a longitudinal study design. Assesment at 3 months included observation of father-child interaction.Key outcome measures: 24 month score on the Mental Development Index (MDI) of the Bayley Scales of Infant DevelopmentStatistical analysis: Correlational analysis of paternal interaction measures at 3 and 24 months was completed. Additionally, independent simple linear analyses and PROCESS macro tool modeling were done to examine effects of covariates.The important finding from the study was that paternal-infant interaction at 3 months of age predicted important dimensions of infant mental development.Fathers who demonstrated more engagement, sensitivity and less control at 3 months had infants with greater scores on the Mental Development Index at 24 months.That authors note in the discussion section "The results of this study indicate that specific dimensions of father-child interactions at both time points are associated with MDI scores even when adjusting for paternal depression, age and education, and maternal sensitivity and infant age."The take home message in this study is that Dad's make a difference in infant development. As the authors note, supporting paternal interaction may be a key prevention measure in infant development.Readers with more interest in this study can access the free full-text manuscript by clicking on the PMID link in the citation below.Follow me on Twitter @WRY999Photo of paternal spider monkey and infant is from my photography files. Follow me on Instagram at WRY999You can find all my Brain Post blog posts and highlight Twitter posts on my Facebook Page Neuroscience Medicine.Sethna V, Perry E, Domoney J, Iles J, Psychogiou L, Rowbotham NEL, Stein A, Murray L, & Ramchandani PG (2017). FATHER-CHILD INTERACTIONS AT 3 MONTHS AND 24 MONTHS: CONTRIBUTIONS TO CHILDREN'S COGNITIVE DEVELOPMENT AT 24 MONTHS. Infant mental health journal PMID: 28449355... Read more »

  • May 17, 2017
  • 02:48 AM

EEG abnormalities and "high functioning" autism

by Paul Whiteley in Questioning Answers

I'm not a great fan of the term 'functioning' when it comes to autism (see here) hence the quote marks around high-functioning in the title of this post. Yes, I understand the message that it's trying to convey and that we don't have viable alternatives at the moment. It just however seems a little sweeping in terms of 'generalised' describing and labelling of people...No mind. Today I'd like to bring the paper by Özdem Ertürk Çetin and colleagues [1] to your attention and the observation that their results "support the fact that EEG abnormalities are observed at a higher rate also in ASD [autism spectrum disorder] with a better functionality." EEG - electroencephalographic or electroencephalogram - refers to the recording of electrical activity in the brain. Although in small amounts, our cells use electrical signals to message each other; said activity in the brain can be picked up and recorded using some rather sensitive equipment. EEGs are the method of choice when it comes to investigating epilepsy or related seizure disorders (such conditions are epitomised by abnormal electrical activity between cells).The connection between autism and epilepsy / seizure disorder is one that has persisted for many years (see here); even now to the point where research is starting to talk about autism / autistic traits being a feature of some cases of epilepsy (see here). Quite a bit of the research looking at autism and epilepsy has tended to suggest that epilepsy may be a little more over-represented for those towards the more severe end of the autism spectrum (i.e. in relation to presentation of symptoms and the presence of some degree of learning / intellectual disability). The Ertürk Çetin findings report that even in those with described 'better functionality' there may be disturbances in relation to the measurement of EEGs.Looking for "the presence of EEG abnormalities in sixteen children diagnosed with high-functioning ASD" researchers reported that whilst none of the participants had clinical seizures (the overt expression of epilepsy) "5 patients (31.3%) were detected to have EEG abnormalities." Bearing in mind the quite small participant numbers and the fact that no control groups (asymptomatic or otherwise) were included for comparisons, this is quite an important finding. I agree with the authors when they say that: "The potential impact of EEG abnormalities on cognition and behavior, and the risk of epilepsy should be considered during long-term follow-up of these patients." In other words, whenever a diagnosis of autism or ASD is received, one should always consider the possibility that a heightened risk of epilepsy / seizure / abnormal EEG patterns might also be a feature of presentation irrespective of "functioning" status.----------[1] Ertürk Çetin Ö. et al. EEG abnormalities and long term seizure outcome in high functioning autism. Acta Neurol Belg. 2017 Apr 26.----------Ertürk Çetin Ö, Korkmaz B, Alev G, & Demirbilek V (2017). EEG abnormalities and long term seizure outcome in high functioning autism. Acta neurologica Belgica PMID: 28447214... Read more »

  • May 16, 2017
  • 05:02 AM

IMFAR, the autism numbers game and 12% showing 'optimal outcome'

by Paul Whiteley in Questioning Answers

A post recently published on the Spectrum website led to my blogging entry today, and the observation that: 'Alternative screen finds high autism prevalence in U.S. state'.Discussing results delivered at IMFAR 2017 the research in question was that presented by Laura Carpenter and colleagues [1] (someone with quite a track record in autism research). This was a conference presentation and seemingly not yet peer-reviewed publication, so one needs to be a little cautious about making big claims just yet. That being said, there have been research hints that these results would be forthcoming [2] around this time.The headline finding was that the prevalence of autism spectrum disorder (ASD) in one particular part of the United States for the birth year 2004 was probably quite a bit higher than that previously reported/estimated based on initial screening for possible ASD and then actual assessment. Details of the initiative used in this research - the South Carolina Children’s Educational Surveillance Study (SUCCESS) - can be found here.Some 4100 children were "screened for ASD using the Social Communication Questionnaire." Those who were deemed 'at risk' for autism and a small proportion of those not hitting those *might be autism* thresholds were asked back for a more detailed interview. Although the number of children actually followed-up and interviewed who were eligible for further assessment was not particularly great, the authors were able to draw up an estimated prevalence of autism based on those who did complete the study. The figure: "ASD prevalence in this sample is 3.62%" roughly equivalent to 1 in 28 children. I say this in the context that in the United States and elsewhere, autism rates and/or numbers of cases are still high (see here and see here) and acknowledgement of the implications of such increases when it comes to services such as education, healthcare and the like.The Spectrum article focuses quite a bit on the participation rate noted in the Carpenter study but another snippet of information is also included in the conference abstract that is worthy of discussion. A detail that reads: "Six children (6/52; 12%) had a clear developmental history of ASD but did not display clinically significant symptoms at the time of participation in this study." Further: "12% with a history of ASD no longer had significant ASD-related symptoms, providing further support for the potential for optimal outcomes in some individuals."I'm rather interested in that 12% figure with 'optimal outcome'. Optimal outcome describes cases where a clear indication/diagnosis of autism has been seen/received, but for whatever reason(s) diagnostic thresholds are not longer met at a future assessment point. I've covered this group quite a few times on this blog, most notably in relation to a previous estimate of 9% of those diagnosed with autism potentially falling into this category (see here). Appreciating that such data challenges the assumption that *all* autism is a lifelong condition (indeed, stretching across the entire autism spectrum - see here), I'd reiterate that those described as being 'optimal outcomers' represent an important subgroup on the autism spectrum in these days of plural autisms (see here). Not least is the question: Why? Why do these children not maintain their diagnosis and what lessons (if any) can be learned for the wider autism spectrum, particularly also in the context that various quite disabling comorbidities might also be 'reduced' alongside core autism symptoms in this group.We await formal peer-reviewed publication of the Carpenter findings and perhaps some further details.To close, upon introducing my brood to the music of Kate Bush, I am yet again reminded just how good a singer/performer she really is...----------[1] Carpenter LA. et al. The Prevalence of Autism Spectrum Disorder in School Aged Children: Population Based Screening and Direct Assessment. IMFAR 2017.[2] Carpenter LA. et al. Screening and direct assessment methodology to determine the prevalence of autism spectrum disorders. Ann Epidemiol. 2016 Jun;26(6):395-400.----------Carpenter LA, Boan AD, Wahlquist AE, Cohen A, Charles J, Jenner W, & Bradley CC (2016). Screening and direct assessment methodology to determine the prevalence of autism spectrum disorders. Annals of epidemiology, 26 (6), 395-400 PMID: 27230493... Read more »

Carpenter LA, Boan AD, Wahlquist AE, Cohen A, Charles J, Jenner W, & Bradley CC. (2016) Screening and direct assessment methodology to determine the prevalence of autism spectrum disorders. Annals of epidemiology, 26(6), 395-400. PMID: 27230493  

  • May 15, 2017
  • 04:33 AM

Intestinal dysbiosis, irritable bowel syndrome and ME/CFS

by Paul Whiteley in Questioning Answers

I don't want to spend too much time talking about yet another paper from the research tag-team that is Hornig & Lipkin [1] (open-access) on the topic of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). But this latest addition to their research repertoire (see here) is deserving of several comments.Not least are the observations made by the authors - including one Brent Williams who some might remember from autism research history (see here) and Jose Montoya who has also made a mark in CFS/ME research circles (see here) - on how the collected wee beasties that inhabit our gastrointestinal (GI) tract might have some role to play when it comes to at least some cases of CFS/ME. Yes it's gut microbiome research time again.The press release accompanying the paper by Dorottya Nagy-Szakal and colleagues can be seen here. The long-and-short of it was that: "Independent of IBS [irritable bowel syndrome], ME/CFS is associated with dysbiosis and distinct bacterial metabolic disturbances that may influence disease severity." Further: "Plasma cytokines did not define ME/CFS disease groups in our cohort." There could be some good reasons for that last sentence looking at immune-related molecules on the basis of other study results (see here) but further investigations are required.I have to say that outside of the observations that particular types of bacteria seem to be more or less prevalent in cases of CFS/ME (yet again) I was rather more interested in the finding that over 40% of the cohort also met criteria for IBS. I say that on the basis that I've already talked about 'abdominal discomfort syndrome' as a feature of some CFS/ME (see here) alongside findings that certain foods *might* also play a role in the bowel symptoms accompanying CFS/ME (see here).In these days of increasing pluralisation of spectrums (the autisms, the schizophrenias, etc) it is probably also quite useful to think about pluralising the diagnostic label CFS/ME too. Assuming we can get the diagnostic criteria right (see here) we could have a phenotype of CFS/ME that, for example, has a stronger bowel-related clinical signature than other forms. The further implications that the GI tract might play a role in CFS/ME in relation to either primary or secondary symptoms might also inform intervention. So, we kinda know that use of probiotics might be something to think about for some cases of IBS (see here). There is also some preliminary evidence that certain probiotics might also impact on some of the 'psychological' features (careful with that term) which can accompany CFS/ME [2]. The possibility of connections exist and therefore require further scientific exploration.----------[1] Nagy-Szakal D. et al. Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. 2017; 5: 44.[2] Rao AV. et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009 Mar 19;1(1):6.----------Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG, Komaroff AL, Levine S, Montoya JG, Peterson DL, Ramanan D, Jain K, Eddy ML, Hornig M, & Lipkin WI (2017). Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome, 5 (1) PMID: 28441964... Read more »

Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG, Komaroff AL, Levine S, Montoya JG.... (2017) Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome, 5(1), 44. PMID: 28441964  

  • May 13, 2017
  • 04:42 AM

Welcoming zonulin into autism research

by Paul Whiteley in Questioning Answers

I was VERY happy to read the paper published by Erman Esnafoglu and colleagues [1] suggesting that: "zonulin, which regulates intestinal permeability, plays a role in the development of symptoms of ASD [autism spectrum disorder]."Zonulin - something that "can be used as a biomarker of impaired gut barrier function for several autoimmune, neurodegenerative, and tumoral diseases" [2] - is a compound that I've been interested in for a while on this and other blogs (see here). The primary reason for the interest is that connection to intestinal permeability and how 'leaky gut' may well show some relevance to some autism (see here and see here). The thing that was up-to-now missing from the research chatter about intestinal hyperpermeability and autism was the measurement of zonulin on the basis that elevated levels of zonulin show a connection to dietary elements such as gliadin (a facet of gluten) [3]. This is particularly relevant because previous data has observed a possible link between use of a gluten-free diet and a reduction in intestinal permeability in relation to autism [4]. All this is [peer-reviewed] research music to my ears (see here)...Esnafoglu et al set about measuring serum levels of zonulin in 32 participants diagnosed with an autism spectrum disorder (ASD) compared with 33 not-autism controls. Yet again, the words 'healthy controls' are used by the authors to define the control group and yet again, the assumption is that those participants with autism are somehow 'unhealthy'. Researchers, please just call it what it is: not-autism controls (the term 'neurotypical' also tells us nothing about control groups either). Measurement of zonulin was via ELISA (enzyme-linked immunosorbent assay) and researchers also threw in a measure of autism severity based on use of the Childhood Autism Rating Scale (CARS).Results: well, the results seemed to be in the expected direction: "Serum zonulin levels were significantly higher in the patients with ASD (122.3 ± 98.46 ng/mL) compared with the healthy controls (41.89 ± 45.83 ng/mL)." Authors also identified a fairly healthy correlation between the CARS score and zonulin levels. These results imply that issues with intestinal permeability - leaky gut - seem to be present in relation to at least some autism. A shocker, I know.Obviously there is more research to do in this area; not least to increase the sample size, look at dietary intake/status as a function of zonulin measurement and explore the possibility that the genetics of zonulin production might also be *involved* in some autism [5]. I might add that other research on zonulin in relation to diagnoses not necessarily uncommon to autism might also be revealing (see here).Insofar as what to do about elevations in zonulin as and when detected in cases of autism, well the dietary link to zonulin production implies that the horror that is a gluten-free (GF) diet might be something to consider. The suggestion of a 'bacterial link' to zonulin production also suggests another possible intervention target in these days of gut microbiomes and autism (see here) although I think we have to be slightly careful about the use of some preparations. There is also another avenue for research speculation based on the development of zonulin (receptor) inhibitors such as Larazotide acetate [6] (otherwise known as AT-1001). With no medical or clinical advice given or intended, the evidence base for this zonulin-affecting compound is looking promising [7] with much more to come...In conclusion, zonulin has arrived on the autism research scene, and I'm expecting to see more peer-reviewed science on this topic in future times. Intestinal hyperpermeability, diet and [some] autism looks to be squarely back on the research agenda.----------[1] Esnafoglu E. et al. Increased Serum Zonulin Levels as an Intestinal Permeability Marker in Autistic Subjects. J Pediatrics. 2017. May 11.[2] Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Annals of the New York Academy of Sciences. 2012; 1258(1) :25-33.[3] Lammers KM. et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008 Jul;135(1):194-204.e3.[4] de Magistris L. et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr. 2010 Oct;51(4):418-24.[5] Tripathi A. et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16799-804.[6] Fasano A. Intestinal Permeability and its Regulation by Zonulin: Diagnostic and Therapeutic Implications. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012;10(10):1096-1100.[7] Leffler DA. et al. Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial. Gastroenterology. 2015; 148: 1311-1319.----------Esnafoglu, E., Cırrık, S., Ayyıldız, S., Erdil, A., Ertürk, E., Daglı, A., & Noyan, T. (2017). Increased Serum Zonulin Levels as an Intestinal Permeability Marker in Autistic Subjects The Journal of Pediatrics DOI: 10.1016/j.jpeds.2017.04.004... Read more »

Esnafoglu, E., Cırrık, S., Ayyıldız, S., Erdil, A., Ertürk, E., Daglı, A., & Noyan, T. (2017) Increased Serum Zonulin Levels as an Intestinal Permeability Marker in Autistic Subjects. The Journal of Pediatrics. DOI: 10.1016/j.jpeds.2017.04.004  

  • May 12, 2017
  • 08:30 AM

Could Parasites Be Causing Prostate Cancer?

by Bill Sullivan in The 'Scope

New study shows that a common parasite called Toxoplasma gondii forms tissue cysts and causes inflammation in mouse prostates. ... Read more »

  • May 12, 2017
  • 03:02 AM

Physical exercise as a nootropic of choice

by Paul Whiteley in Questioning Answers

Nootropic, defined as a 'smart drug' or cognitive enhancer, is generally taken to mean a substance/compound/medicine that has some positive effect(s) on aspects of cognition. I've talked about the possibility that various compounds might fit this bill on this blog (see here for example) but today I'm discussing another quite important potential nootropic: exercise.It was the paper by Joseph Michael Northery and colleagues [1] (open-access) that added exercise to the nootropic categorisation on the premise of their meta-analysis results suggesting that "physical exercise interventions are effective in improving cognitive function in adults aged >50 years, regardless of cognitive status." As you can imagine, findings such as that tend to generate news headlines as per this one.Including the results of some 39 studies where exercise and cognition were included as watchwords and trials were of the randomised-controlled design, researchers set about analysing the collected data covering various types of exercise and various cognitive outcomes. Aside from some issues with various forms of bias, most prominently with regards to blinding(!), they concluded that various types of exercise seemed to positively impact on cognitive functions. Particularly notable were the positive effects on executive functions: "a set of cognitive processes responsible for the initiation and monitoring of goal-orientated behaviours" and aspects of memory via the use of resistance training (i.e. using weights). Other more aerobic exercise regimes also seemed to have positive effects on other aspects of cognition too. It seems some combination of aerobic and resistance exercise regimes might provide the best generalised advice according to the authors "of at least moderate intensity and at least 45 min per session, on as many days of the week as possible." Just going back to that resistance training - executive functioning link being proposed, I wonder whether there may be other investigations to be carried out here with specific labels in mind [2].Added to other research talking about 'exercise as medicine' (see here) and more particularly that exercise *might* have some important effects for aspects of psychological health and wellbeing (see here and see here for examples) there is a peer-reviewed, evidence-based picture emerging. It suggests that messages about moving more (see here) as being important for weight and BMI might be only the tip of iceberg.And although not for everyone, I'm minded to yet again extol the virtues of the martial arts which also might have some "positive effect on some aspects of cognition" [3] (even for those under 50 years old with middle-aged hips like mine)...----------[1] Northey JM. et al. Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis. Br J Sports Med. 2017. April 24.[2] Demetriou EA. et al. Autism spectrum disorders: a meta-analysis of executive function. Molecular Psychiatry. 2017. April 25.[3] Fabio RA. & Towey GE. Cognitive and personality factors in the regular practice of martial arts. J Sports Med Phys Fitness. 2017 May 5.----------Northey, J., Cherbuin, N., Pumpa, K., Smee, D., & Rattray, B. (2017). Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis British Journal of Sports Medicine DOI: 10.1136/bjsports-2016-096587... Read more »

  • May 11, 2017
  • 03:08 AM

Could an "ill-state" associated with anorexia nervosa mimic the symptoms of autism?

by Paul Whiteley in Questioning Answers

The question posed in the title of this post 'Could an "ill-state" associated with anorexia nervosa mimic the symptoms of autism?' stems from the findings reported by Heather Westwood and colleagues [1] (open-access).They continued a research theme looking at the potential 'overlap' when it comes to autism and eating disorders such as anorexia nervosa (AN) (see here). Notably, researchers questioned whether the finding that some 50% of their cohort "scored above the clinical cut-off on the ADOS-2" but "when developmental history was obtained, only 10% met diagnostic criteria for ASD [autism spectrum disorder]" could be due to "the ill-state associated with AN."The Westwood paper is open-access so doesn't need any further grand explanations from me. The research caveats alongside relying on quite a small cohort - "40 females aged between 12 and 18" - were that this was a snapshot study not a longitudinal one and whilst relying on data other than that just linked to the presence of autism traits, they did not control for things like social anxiety "which could lead to high scores on the ADOS-2." Interesting.On the question of whether 'active AN' (please pardon my lack of knowledge on this topic) might have the ability to 'provoke' autistic traits, I have to say that I'm quite intrigued. This might have a few, quite important, implications not least that (a) autistic traits can be 'acquired' as per what has been noted under other different circumstances (see here and see here for examples) and (b) the potential stability of said traits might not be particularly stable for everyone at every time (see here). On that last point, we do need a lot more data as to what happens/happened when AN is treated/managed or goes into remission for example and any subsequent impact on autistic traits.It's too early to start talking mechanisms when it comes to AN and autistic traits in light of this data alone. I might also venture into the idea that other comorbidities than can appear alongside AN might also have some impact on clinical presentation (see here) and are also in need to further investigation in the context of any eating disorders - autism correlation. Indeed, there are potentially lots of variables that need to be kept in mind (see here and see here) before any sweeping generalisation are made...----------[1] Westwood H. et al. Assessing ASD in Adolescent Females with Anorexia Nervosa using Clinical and Developmental Measures: a Preliminary Investigation. J Abnorm Child Psychol. 2017 Apr 17.----------Westwood, H., Mandy, W., Simic, M., & Tchanturia, K. (2017). Assessing ASD in Adolescent Females with Anorexia Nervosa using Clinical and Developmental Measures: a Preliminary Investigation Journal of Abnormal Child Psychology DOI: 10.1007/s10802-017-0301-x... Read more »

  • May 10, 2017
  • 02:35 AM

Conviction for violence and autism: comorbidity counts

by Paul Whiteley in Questioning Answers

I tread carefully when discussing the results published by Ragini Heeramun and colleagues [1] on the topic of "whether autism is associated with convictions for violent crimes" and "the associated risk and protective factors." Carefully because, as I've indicated on other occasions (see here), people commit crimes not labels, and sweeping generalisations about labels, specific types of crime and/or the concept of 'dangerousness' tend to do very little to help anyone in the long term.Still, I do think it is important that issues such as offending in the context of autism spectrum disorder (ASD) are not brushed under the carpet. I say this bearing in mind that a few high profile cases where autism has been mentioned alongside have been highlighted in the media recently here in Blighty (see here and see here). Indeed, in these days of cyber-terrorism linked to extremism for example, I'd like to see quite a bit more scientific investigation into the ways of protecting those on the autism spectrum from being lured into such activities alongside studies on the possible hows-and-whys of people entering into such behaviours.Heeramun et al relied on data from the Stockholm Youth Cohort where some 5,700 participants had a recorded ASD diagnosis. Data was cross-referenced with that from the Swedish National Crime Register to ascertain how many people were charged with offences where violence was a factor. Comparing those with autism with those with not-autism, researchers concluded that: "Individuals with autism, particularly those without intellectual disability, initially appeared to have a higher risk of violent offending." They do temper that finding with the observation that "these associations markedly attenuated after co-occurring attention-deficit/hyperactivity disorder (ADHD) or conduct disorder were taken into account" suggesting that comorbidity might count. Indeed, this data tallies with other independent findings suggesting that a range of 'adverse' life events can be a significant feature of ADHD and conduct disorder in the long-term (see here) and for example, that autism and ADHD in the prison population should considered (see here).Alongside, authors talked about how various other factors might also influence risk of violent offending ("parental criminal and psychiatric history and socioeconomic characteristics") and importantly, how: "Better school performance and intellectual disability appeared to be protective." That intellectual (learning) disability accompanying autism seems to be protective against conviction for a violent crime with autism in mind is probably due in part to the increased supervision given to such individuals. This is a point that has been raised in previous peer-reviewed research too (see here).The take-away messages are once again, sweeping generalisations about all autism being *linked to* violent crime are not needed and that comorbidity might count (as it seems to on many occasions) when it comes to variables being linked to autism (see here for another example). As with such crime in the general population, there are a myriad of often quite individual factors contributing to such behaviours, but alongside: "Better understanding and management of comorbid psychopathology in autism may potentially help preventive action against offending behaviors in people with autism."----------[1] Heeramun R. et al. Autism and Convictions for Violent Crimes: Population-Based Cohort Study in Sweden. JAACAP. 2017. April 3.----------Heeramun, R., Magnusson, C., Gumpert, C., Granath, S., Lundberg, M., Dalman, C., & Rai, D. (2017). Autism and Convictions for Violent Crimes: Population-Based Cohort Study in Sweden Journal of the American Academy of Child & Adolescent Psychiatry DOI: 10.1016/j.jaac.2017.03.011... Read more »

Heeramun, R., Magnusson, C., Gumpert, C., Granath, S., Lundberg, M., Dalman, C., & Rai, D. (2017) Autism and Convictions for Violent Crimes: Population-Based Cohort Study in Sweden. Journal of the American Academy of Child . DOI: 10.1016/j.jaac.2017.03.011  

  • May 9, 2017
  • 04:24 AM

"Medical Conditions in the First Years of Life Associated with Future Diagnosis of ASD"

by Paul Whiteley in Questioning Answers

I rank the paper by Stacey Alexeeff and colleagues [1] (open-access available here) as being in the 'pretty important' category when it comes to hierarchy in autism research. Not only because of their use of data derived from Kaiser Permanente (KP) (quite a large US healthcare provider that has some autism research history) including some "3911 ASD [autism spectrum disorder] cases and 38,609 controls" but also because some of the findings reiterate what is already 'known' about in relation to autism and how various medical conditions might be quite important to at least some 'types' of autism. These results are also being presented at IMFAR 2017 (see here) which will be opening its doors very soon...The Alexeeff paper is open-access but a few choice details are worthwhile pulling out:As per those participant numbers, the authors confirmed that "ASD cases were defined as children with either (a) an ASD diagnosis from an ASD specialist or (b) two or more ASD diagnoses from non-specialists, separated in time." This contrasted with controls who "were required to never have had an ASD diagnosis as of June 2012" (the period of study covered those born between 2000 and 2009).The medical conditions screened for in participant records were quite wide-ranging: "Over 1000 ICD-9 codes were grouped into 79 medical conditions (e.g., constipation) within 19 domains (e.g., gastrointestinal)" and importantly, relied on physician/clinician input. Researchers ascertained how frequently said medical conditions occurred in each of the groups: "whether certain medical conditions occurring in early childhood were associated with a higher risk of future ASD diagnosis."Results: "38 of the 79 medical conditions had statistically significant associations with ASD risk after multiple testing adjustment." These conditions ranged from various types/forms of developmental delay (language, learning, motor) to more somatic conditions: "nutrition, genetic, ear nose and throat, and sleep conditions." It's also worth noting that some types of diagnosis/conditions displayed only a weak association with subsequent risk of ASD including that related to asthma (previously discussed quite a bit on this blog).Researchers also looked at what clusters of medical conditions might be associated with lower or higher likelihood of an ASD diagnosis being given. They concluded that: "Developmental delay and mental health condition clusters were associated with the highest relative risks of ASD." They further suggest that "combinations of medical comorbidities could aid in risk stratification for ASD prior to ASD diagnosis using a supervised clustering analysis based on machine-learning methods." Machine learning yet again, applied to autism research eh?There's little more for me to discuss about this work other than to say that much more targeted research is needed to build on these latest findings from Alexeeff and colleagues. Coinciding with the ideas that (i) autism rarely exists in some sort of diagnostic vacuum (see here) and that (ii) autism genes are not necessarily just genes for autism (see here) (indeed a topic rising in research importance [2]) the lessons to be learned are becoming a little clearer. I might also focus a little more on those somatic diagnoses discussed in the Alexeeff paper as being quite important to the clinical picture when it comes to autism. Y'know how various medical comorbidities are indeed over-represented when it comes to autism and how appropriate screening and management/treatment [3] should be offered when and where they are identified (see here) save any further healthcare inequalities arising...To close, I appreciate that there are quite a lot of opinions out there about a certain US autism organisation, but a recent document of theirs talking about the various conditions/comorbidities that can follow a diagnosis of autism (see here) deserves an airing. Not that they were however the first group to talk about this important part of the autism spectrum (see here) but better late than never...----------[1] Alexeeff SE. et al. Medical Conditions in the First Years of Life Associated with Future Diagnosis of ASD in Children. J Autism Dev Disord. 2017 Apr 22.[2] Diaz-Beltran L. et al. Cross-disorder comparative analysis of comorbid conditions reveals novel autism candidate genes. BMC Genomics 2017. 18: 315.[3] Flor J. et al. Developmental functioning and medical Co-morbidity profile of children with complex and essential autism. Autism Res. 2017 May 5.----------Alexeeff SE, Yau V, Qian Y, Davignon M, Lynch F, Crawford P, Davis R, & Croen LA (2017). Medical Conditions in the First Years of Life Associated with Future Diagnosis of ASD in Children. Journal of autism and developmental disorders PMID: 28434058... Read more »

Alexeeff SE, Yau V, Qian Y, Davignon M, Lynch F, Crawford P, Davis R, & Croen LA. (2017) Medical Conditions in the First Years of Life Associated with Future Diagnosis of ASD in Children. Journal of autism and developmental disorders. PMID: 28434058  

  • May 8, 2017
  • 05:45 PM

Let those who never smelled bad cast the first stone

by Aurametrix team in Aurametrix Blog

Analysis of our metabolism is crucial to comprehending the responses of our genes and microbes to the stresses of daily life, and to elucidating the causes and consequences of health and disease. And measurement of urinary metabolites - small molecules produced from foods, drinks, drugs, environmental contaminants, bodily waste products and bacterial by-products - is key to the analysis. We applied this approach to an elusive condition that has always evaded diagnosis: s [...] ... Read more »

Bouatra, S., Aziat, F., Mandal, R., Guo, A., Wilson, M., Knox, C., Bjorndahl, T., Krishnamurthy, R., Saleem, F., Liu, P.... (2013) The Human Urine Metabolome. PLoS ONE, 8(9). DOI: 10.1371/journal.pone.0073076  

Irene S. Gabashvili. (2017) Raw Data from Clinical Trial NCT02692495. Mendeley Data. info:/DOI: 10.17632/8bk6h6bmkr.1

  • May 8, 2017
  • 03:04 AM

Vitamin D genes and autism

by Paul Whiteley in Questioning Answers

"Vitamin D deficiency is a putative environmental risk factor for autism spectrum disorder (ASD)."And..."We provide straightforward genetic evidences for the first time that VDRGs [vitamin D-related genes] with a strong degree of DNM [de novo mutations] burden in ASD and DNMs of VDRGs could be involved in the mechanism underlying in ASD pathogenesis."That was the research bottom line reported on by Jinchen Li and colleagues [1] examining an important part of the whole 'vitamin D - autism' link (see here). Specifically, how outside of just looking at functional levels of vitamin D in relation to autism (see here) and implying that groups on the autism spectrum may not be getting enough vitamin D through sunlight exposure or diet, there may be other underlying issues to consider. As other authors have hinted, the genetics of vitamin D metabolism may also be part and parcel of the autism - vitamin D story (see here).This time around, researchers "analyzed publicly-available DNMs from 4,327 ASD probands and 3,191 controls." Among those DNMs - alterations to the genetic code present in probands but not extended family members - "18 of the VDRGs were found to harbor recurrent functional DNMs in the probands, compared with only one in the controls." In other words, small 'glitches' in the genes thought to be involved in vitamin D metabolism were more frequently present in the autism group than the not-autism group. Said glitches *may* have the ability to affect the working of those vitamin D metabolising genes with onward effects.This is interesting work. It kinda reiterates that (i) vitamin D and the metabolism of vitamin D might be important for at least some parts of the autism spectrum and, (ii) issues with deficiency or insufficiency of vitamin D metabolites in relation to autism may be the product of both genetic and environmental issues. We obviously need to see more investigations done in this area; not least to define how widespread said genetic issues affecting vitamin D metabolism might be in relation to the very wide and very heterogeneous autism spectrum. I'd put a bet on such issues perhaps affecting only part of the autism spectrum and perhaps related to one or more phenotypes. Other authors seem to think so too [2].  I'd also wager that something quite important might emerge when it comes to the specificity of any findings too (see here).The other question that needs to be answered is what can be done as and when issues with vitamin D metabolising genes are detected. Does this mean that additional supplementation of vitamin D (in it's typically supplemented form(s)) is unlikely to be of use (bearing in mind the recent data in this area) as a result of those DNMs? As with everything related to autism, simple answers to seemingly simple questions are very, very unlikely...----------[1] Li J. et al. Vitamin D-related genes are subjected to significant de novo mutation burdens in autism spectrum disorder. Am J Med Genet B Neuropsychiatr Genet. 2017 Apr 13.[2] Gillberg C. et al. The role of cholesterol metabolism and various steroid abnormalities in autism spectrum disorders: A hypothesis paper. Autism Res. 2017 Apr 12.----------Li J, Wang L, Yu P, Shi L, Zhang K, Sun ZS, & Xia K (2017). Vitamin D-related genes are subjected to significant de novo mutation burdens in autism spectrum disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics PMID: 28407358... Read more »

Li J, Wang L, Yu P, Shi L, Zhang K, Sun ZS, & Xia K. (2017) Vitamin D-related genes are subjected to significant de novo mutation burdens in autism spectrum disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. PMID: 28407358  

  • May 6, 2017
  • 05:03 AM

Congenital heart disease and autism and ADHD: Taiwan wades in

by Paul Whiteley in Questioning Answers

"The incidence rates of perinatal comorbidities, EDD [early developmental disorders], ADHD [attention-deficit hyperactivity disorder], and ASD [autism spectrum disorder] were higher in the CHD [congenital heart disease] group than in the control group."So said the findings reported by Pei-Chen Tsao and colleagues [1] investigating an issue that has cropped up more than once on this blog in relation to the developmental/behavioural correlates possibly associated with a diagnosis of congenital heart disease (CHD) (see here and see here). As per the title of this post, the scientific weight of the Taiwanese National Health Insurance Research Database (NHIRD) was brought into this research area, examining the developmental records of some 3500 under 18-year olds diagnosed with CHD compared with over 14,000 age- and sex-matched controls. Researchers looked for both diagnoses of ADHD and ASD in participant records as well as: "Comorbid perinatal conditions and early developmental disorders (EDD) that were diagnosed before ADHD and ASD diagnosis."Results: well, just about everything looked for in the groups was found more frequently in the CHD grouping even after adjustment for various potentially confounding variables. Authors also reported that: "the risk for ADHD... and ASD... was greatly increased in CHD subjects with EDD than in non-CHD subjects without EDD" and onwards something of a cumulative effect when EDD and CHD were found comorbid.The implications of such results? Well, yet again I'll refer you back to the first time I talked about CHD and autism on this blog (see here) in terms of possible hows-and-whys and future research directions. The added issue of preferential screening for developmental issues/diagnoses when a diagnosis of CHD is received also comes to the forefront (yet again). Said screening might also include other elements too [2]...----------[1] Tsao PC. et al. Additive effect of congenital heart disease and early developmental disorders on attention-deficit/hyperactivity disorder and autism spectrum disorder: a nationwide population-based longitudinal study. Eur Child Adolesc Psychiatry. 2017 Apr 17.[2] Wu XL. et al. Chromosome microarray analysis in the investigation of children with congenital heart disease. BMC Pediatrics. 2017; 17: 117.----------Tsao PC, Lee YS, Jeng MJ, Hsu JW, Huang KL, Tsai SJ, Chen MH, Soong WJ, & Kou YR (2017). Additive effect of congenital heart disease and early developmental disorders on attention-deficit/hyperactivity disorder and autism spectrum disorder: a nationwide population-based longitudinal study. European child & adolescent psychiatry PMID: 28417257... Read more »

  • May 5, 2017
  • 02:55 AM

Trends in ADHD medication use in the US and Europe: is this a bad thing?

by Paul Whiteley in Questioning Answers

I don't want to dwell too much on the findings reported by Christian Bachmann and colleagues [1] observing that in five Western countries - Denmark, Germany, the Netherlands, the United Kingdom (UK) and the United States (US) - ADHD (attention-deficit hyperactivity disorder) medication use between 2005/2006-2012 was on the increase. But I do think it is important to mention some of the implications from such figures and some of the positives and negatives associated with such generated data.OK, first things first. The general consensus is that the prevalence of ADHD in many parts of the world is on the up compared with say a decade or two ago. We can um-and-ah about whether this is a true increase in cases or whether through changes to the way ADHD is diagnosed for example, the figures are artificially inflated (see here). Indeed, whether for some - not by any means all - a diagnosis of ADHD is merely a means to an end (see here). Suffice to say that many studies either looking directly at rates of ADHD or via analysis of medication prescribing patterns suggest that more cases are being diagnosed these days. And that includes the use of ADHD as a comorbid diagnosis in relation to labels such as autism for example (see here) on the back of the important discussions about autism not typically presenting in some sort of diagnostic vacuum (see here).The use of medication prescribing patterns to track estimated ADHD prevalence is the preferred method employed by Bachmann et al who concluded that: "ADHD medication use prevalence increased from 1.8% to 3.9% in the Netherlands cohort (relative increase: +111.9%), from 3.3% to 3.7% in the US cohort (+10.7%), from 1.3% to 2.2% in the German cohort (+62.4%), from 0.4% to 1.5% in the Danish cohort (+302.7%), and from 0.3% to 0.5% in the UK cohort (+56.6%)."So, the positives from the Bachmann data. Well, accepting that ADHD is a label that, in the longer term, has been associated with heightened risk for all-manner of adverse life events (see here and see here for examples) I don't think anyone would argue that with the availability of good, safe, reliable treatment options (see here) and that such management avenues should be properly utilised. I know some people might be a little reluctant to want to medicate children for example, but the data from the various collected studies on something like methylphenidate use (typically indicated for ADHD or the presentation of ADHD-type behaviours) generally regards the medicine as safe and well tolerated albeit with monitoring and good medicines management implied. And by saying that I'm not suggesting that medication is/should be the only management option when it comes to ADHD (see here and see here for other examples). My reading of the Bachmann data is that prescribing clinicians are doling out more prescriptions for managing ADHD but this is a reflection of (a) greater recognition of ADHD and ADHD behaviours and/or (b) the value of prescribing such medicines to things like quality of life of recipients and their families.The negatives... well, it wouldn't be difficult to suggest that with the realisation that quite a few ADHD medications have a good overall safety/response profile, clinicians perhaps become a little more 'comfortable' with their prescription over a wider range of presenting behaviours without necessarily looking at other options first. The fact for example, that Bachmann et al observed: "ADHD medication use was highest in 10-14-year olds", a special time when quite a few biological changes are on-going, could be interpreted as such medication use being a pharmacological 'crutch' during such a period. I don't know enough about ADHD to comment on whether its presentation is 'enhanced' as and when puberty hits but if it's anything like other labels [2]...Reiterating that medication is not the only intervention option when it comes to ADHD and that one still needs to be cautious about the use of psychoactive substances typically being part of ADHD pharmacotherapy, I am airing on the more positive implications of the Bachmann findings rather than the negatives. Like many other discussions about medication use under various different circumstances (see here for example) it's easy to say that such medicines use is growing because of inappropriate or over-zealous use and should be curbed. But such medications often afford a real increase in quality of life when it comes to ADHD and, bearing in mind those enhanced risks typically associated with the label of ADHD, I can't in all honesty say that greater medication use is specifically detrimental to individuals personally or in a wider context...----------[1] Bachmann CJ. et al. Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012. Eur Neuropsychopharmacol. 2017 Mar 20. pii: S0924-977X(17)30184-0.[2] Gillberg C. & Schaumann H. Infantile autism and puberty. J Autism Dev Disord. 1981 Dec;11(4):365-71.----------Bachmann CJ, Wijlaars LP, Kalverdijk LJ, Burcu M, Glaeske G, Schuiling-Veninga CC, Hoffmann F, Aagaard L, & Zito JM (2017). Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology PMID: 28336088... Read more »

Bachmann CJ, Wijlaars LP, Kalverdijk LJ, Burcu M, Glaeske G, Schuiling-Veninga CC, Hoffmann F, Aagaard L, & Zito JM. (2017) Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. PMID: 28336088  

join us!

Do you write about peer-reviewed research in your blog? Use to make it easy for your readers — and others from around the world — to find your serious posts about academic research.

If you don't have a blog, you can still use our site to learn about fascinating developments in cutting-edge research from around the world.

Register Now

Research Blogging is powered by SRI Technology.

To learn more, visit